Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

(2013) Robert J Motzer et al.   LANCET ONCOLOGY

Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities

(2012) Roger B. Cohen et al.   INVESTIGATIONAL NEW DRUGS

VEGF Inhibition, Hypertension, and Renal Toxicity

(2012) Suzanne R. Hayman et al.   Current Oncology Reports

Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use

(2011) Ziya Kirkali   BJU INTERNATIONAL

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

Experience with sorafenib and adverse event management

(2010) Joaquim Bellmunt et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors

(2010) Emily S. Robinson et al.   HYPERTENSION

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

(2010) Michael L. Maitland et al.   JNCI-Journal of the National Cancer Institute

Contemporary Clinical Epidemiology of Renal Cell Carcinoma: Insight From a Population Based Case-Control Study

(2010) David C. Miller et al.   JOURNAL OF UROLOGY

Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker

(2010) Emily S. Robinson et al.   SEMINARS IN NEPHROLOGY

VEGF kinase inhibitors: how do they cause hypertension?

(2009) Pankaj Bhargava   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

(2009) M. L. Maitland et al.   CLINICAL CANCER RESEARCH

Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

(2009) Carie S. Facemire et al.   HYPERTENSION

Hypertension and proteinuria: a class-effect of antiangiogenic therapies

(2008) Vincent Launay-Vacher et al.   ANTI-CANCER DRUGS

Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

(2008) N. Steeghs et al.   CLINICAL CANCER RESEARCH

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

(2008) D. D. Hu-Lowe et al.   CLINICAL CANCER RESEARCH

Call to Action on Use and Reimbursement for Home Blood Pressure Monitoring

(2008) Thomas G. Pickering et al.   HYPERTENSION

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

(2008) Shenhong Wu et al.   LANCET ONCOLOGY

Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies

(2008) T. E. Hutson et al.   ONCOLOGIST

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

(2007) J.-J. Mourad et al.   ANNALS OF ONCOLOGY